In cancer, somatic loss of function mutations in KEAP1 or NFE2L2 genes are the most known mechanisms that reduce NRF2-KEAP1 binding and prevent degradation of NRF2 through KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex [45,51]. Here, NFE2L2 is linked to cancer.